TY - JOUR
T1 - Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography
AU - Minami, Daisuke
AU - Takigawa, Nagio
AU - Oda, Naohiro
AU - Ninomiya, Takashi
AU - Kubo, Toshio
AU - Ohashi, Kadoaki
AU - Sato, Akiko
AU - Hotta, Katsuyuki
AU - Tabata, Masahiro
AU - Kaji, Mitsumasa
AU - Tanimoto, Mitsune
AU - Kiura, Katsuyuki
N1 - Funding Information:
Funding to pay the Open Access publication charges for this article was provided by the Ministry of Education, Culture, Sports, Science, and Technology, Japan (15K21185).
Publisher Copyright:
© The Author 2016. Published by Oxford University Press.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Objective: Endobronchial ultrasound-guided transbronchial needle aspiration is of diagnostic value in hilar/mediastinal (N1/N2) lymph node staging. We assessed the utility of endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer patients with N1/N2 lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Methods: Fifty lung cancer patients with N1/N2 disease on 18F-fluorodeoxyglucose positron emission tomography/computed tomography underwent endobronchial ultrasound-guided transbronchial needle aspiration for pathological lymph nodes between November 2012 and April 2015. The diagnostic performance of endobronchial ultrasound-guided transbronchial needle aspiration, lymph node site and size, number of needle passes and complications were evaluated retrospectively from patients' medical records. Malignancy was defined as a maximum standardized uptake value (SUVmax) >2.5. Results: The median longest diameter of the 61 lymph nodes (29 subcarinal, 21 right lower paratracheal, 6 left lower paratracheal, 4 right hilar and 1 upper paratracheal) was 23.4 mm (range: 10.4-45.7); the median number of needle passes was 2 (range: 1-5). There were no severe complications. A definitive diagnosis was made by endobronchial ultrasound-guided transbronchial needle aspiration in 39 patients (31 adenocarcinomas, 3 small-cell carcinomas, 2 squamous-cell carcinomas, 3 large-cell neuroendocrine carcinomas). In the remaining 11 patients, the diagnosis was indefinite: insufficient endobronchial ultrasound-guided transbronchial needle aspiration material was collected in two patients and non-specific lymphadenopathy was confirmed by endobronchial ultrasound-guided transbronchial needle aspiration or thoracotomy in the other nine patients. The mean lymph node SUVmax was 7.09 (range: 2.90-26.9) and was significantly higher in true-positive than in false-positive nodes (P < 0.05, t-test). Non-specific lymphadenopathy was diagnosed by expert visual interpretation of cF-fluorodeoxyglucose positron emission tomography/computed tomography images in five of the nine patients. Conclusion: Endobronchial ultrasound-guided transbronchial needle aspiration accurately diagnoses N1/N2 disease detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
AB - Objective: Endobronchial ultrasound-guided transbronchial needle aspiration is of diagnostic value in hilar/mediastinal (N1/N2) lymph node staging. We assessed the utility of endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer patients with N1/N2 lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Methods: Fifty lung cancer patients with N1/N2 disease on 18F-fluorodeoxyglucose positron emission tomography/computed tomography underwent endobronchial ultrasound-guided transbronchial needle aspiration for pathological lymph nodes between November 2012 and April 2015. The diagnostic performance of endobronchial ultrasound-guided transbronchial needle aspiration, lymph node site and size, number of needle passes and complications were evaluated retrospectively from patients' medical records. Malignancy was defined as a maximum standardized uptake value (SUVmax) >2.5. Results: The median longest diameter of the 61 lymph nodes (29 subcarinal, 21 right lower paratracheal, 6 left lower paratracheal, 4 right hilar and 1 upper paratracheal) was 23.4 mm (range: 10.4-45.7); the median number of needle passes was 2 (range: 1-5). There were no severe complications. A definitive diagnosis was made by endobronchial ultrasound-guided transbronchial needle aspiration in 39 patients (31 adenocarcinomas, 3 small-cell carcinomas, 2 squamous-cell carcinomas, 3 large-cell neuroendocrine carcinomas). In the remaining 11 patients, the diagnosis was indefinite: insufficient endobronchial ultrasound-guided transbronchial needle aspiration material was collected in two patients and non-specific lymphadenopathy was confirmed by endobronchial ultrasound-guided transbronchial needle aspiration or thoracotomy in the other nine patients. The mean lymph node SUVmax was 7.09 (range: 2.90-26.9) and was significantly higher in true-positive than in false-positive nodes (P < 0.05, t-test). Non-specific lymphadenopathy was diagnosed by expert visual interpretation of cF-fluorodeoxyglucose positron emission tomography/computed tomography images in five of the nine patients. Conclusion: Endobronchial ultrasound-guided transbronchial needle aspiration accurately diagnoses N1/N2 disease detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
KW - Endobronchial ultrasound-guided transbronchial biopsy
KW - Endoscopy-respiratory tract
KW - F-fluorodeoxyglucose positron emission tomography/computed tomography
KW - Lung cancer
KW - Lung-RadOncol
KW - Radiology-PET
UR - http://www.scopus.com/inward/record.url?scp=84991818975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991818975&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyw023
DO - 10.1093/jjco/hyw023
M3 - Article
C2 - 27004902
AN - SCOPUS:84991818975
VL - 46
SP - 529
EP - 533
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 6
M1 - hyw023
ER -
